{
    "nctId": "NCT00452673",
    "briefTitle": "Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer",
    "officialTitle": "Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 52,
    "primaryOutcomeMeasure": "Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population",
    "eligibilityCriteria": "For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.\n\nInclusion Criteria:\n\n* Female with advanced breast cancer previously treated with a taxane and an anthracycline\n* No pleural or pericardial effusion\n* Not receiving anticoagulants",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}